Aligos Therapeutics, Inc. - Common stock —— 现金流量表 (NASDAQ:ALGS)

Financials

经营活动产生的现金 -74.26 M-115.66 M-79.39 M-79 M-80.74 M-82.5 M -84.72 M 投资活动产生的现金 32.76 M3.02 M-26.29 M44.98 M-18.28 M-37.83 M 41.17 M 融资活动产生的现金 192.35 M78.68 M164 K88.33 M355 K101.64 M -169 K 自由现金流 -74.26 M-115.66 M-79.39 M-79 M-80.74 M-82.5 M -84.72 M

新闻

H.C. Wainwright维持Aligos Therapeutics股票买入评级，看好pevifoscorvir研发进展

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics股价因乙肝二期研究进展而上涨

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos公布乙肝药物二期研究进展

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos Therapeutics任命James Hassard为首席商务官

Aligos therapeutics appoints James Hassard as chief commercial officer

UBS以肝脏疾病管线为由给Aligos Therapeutics股票首次评级为"买入"

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos报告THR-β激动剂协同减重效果

Aligos reports synergistic weight loss effect with THR-β agonist